hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

Gilead Sciences joins Medicines Patent Pool - shareholders applaud the firm

Get RSS feed of these results

All components of this story

Article
+ Français - Hide

Author: Marie Kostrz, Rue89 [France]

Une centaine de pays pauvres vont enfin pouvoir accéder aux thérapies VIH à bas prix. Le laboratoire californien Gilead a accepté de confier les droits d'une partie de ses brevets à des fabricants de génériques. Un tournant dans le traitement du sida, si d'autres laboratoires suivent son exemple. Gilead est le premier laboratoire à intégrer la fondation suisse Medicines Patent Pool, « communauté de brevets » créée en 2010 par Unitaid, qui négocie les prix des traitements contre le VIH, le paludisme et la tuberculose pour les pays les plus pauvres...Bruno Spire, président d'Aides, espère que cette révolution va inciter les autres laboratoires à rejoindre le « patent pool », notamment Johnson & Johnson ou Merck...

🚫Read the full post here

Article
12 July 2011

Shareholders Applaud Gilead Sciences Licensing Agreement with the Medicines Patent Pool

Author: Interfaith Center on Corporate Responsibility [USA]

...Interfaith Center on Corporate Responsibility (ICCR) today acclaim[s] the decision of Gilead Sciences to become the first pharmaceutical company to join the Medicines Patent Pool. By making licenses available for vital HIV and Hepatitis B drugs...Gilead shows uncommon leadership and sets an example for the entire industry...The Medicines Patent Pool was established in 2010 with the support of UNITAID to improve access to medicines for HIV/AIDS, tuberculosis and malaria -- diseases that disproportionately impact the world’s poorest countries...ICCR Program Director for Human Rights David Schilling [said], “When companies recognize access to affordable life-saving medicines as a basic human right they also acknowledge their responsibility to make whatever adjustments are necessary to their business models to protect this right. Joining the Medicines Patent Pool is a crucial step in that direction.” [Link last checked on 12 Jul 2011]